Patrick Hwu, President and CEO at Moffitt Cancer Center, posted the following on LinkedIn:
“T cells recognize tumors through binding of their T-cell receptors (TCRs) to peptide antigens within MHC molecules.
What is the optimal strength of this receptor binding, known as ‘avidity,’ to mediate antitumor immunity?
In this work from the Srivastava Lab, low avidity T cells were found to drive cancer control, while high-affinity T cells were associated with T cell exhaustion.
This interesting (and unintuitive) insight may help guide future immunotherapy design.”
Low-avidity T cells drive endogenous tumor immunity in mice and humans
Authors: Summit Singhaviranon, Joseph P. Dempsey, Adam T. Hagymasi, Ion I. Mandoiu & Pramod K. Srivastava
